Three companies led by Indian origin entrepreneurs — Qure.ai led by Prashant Warier, CRISPR Therapeutics led by Sam Kulkarni and Vertex Pharmaceuticals led by Reshma Kewalramani — figure among TIME100 Most Influential Companies of 2025.
Vertex Pharmaceuticals was also one of the inaugural recipients of TIME100 Companies Impact Awards for Impact in Health. The new awards recognize five additional standout companies making meaningful contributions in the fields of AI, Health, Sustainability, Equality, and Culture. The firms were selected from applicants that stood out for their bold vision and tangible results, according to Time.
The other four inaugural recipients are: Google DeepMind for Impact in AI, Schneider Electric for Impact in Sustainability, Janngo Capital for Impact in Equality, and The Lego Group for Impact in Culture.
READ: Nik Jhangiani takes over as interim CEO of Diageo (
The TIME100 Most Influential Companies were selected on the basis of a mosaic of qualities, studying impact, innovation, ambition, and success, each in the forms that take shape today.
Indian American-led companies are:
Qure.ai: Healthcare systems around the world can keep up with aging populations and increasing disease rates by deploying AI-backed tools, argues Prashant Warier, CEO and co-founder of Qure.ai.
His India-based startup uses deep-learning technology to interpret diagnostic imaging (think X-rays, ultrasounds and CT scans) and flag early signs of problems like lung cancer, brain trauma, and tuberculosis for further investigation.
“It’s like having a highly-trained assistant that never gets tired and can spot issues immediately,” Warier says. Trained on one of the world’s largest data sets, Qure.ai’s algorithms are as accurate as a radiologist, according to the company, providing crucial insights in rural or developing areas where specialists may not be available.
READ: 5 Indian Americans in inaugural TIME100 Creators list (July 10, 2025)
Qure.ai tools have now been deployed in more than 100 countries and the company has 18 FDA clearances—the greatest number for lung cancer AI in the U.S.—including three new approvals in 2024.
CRISPR Therapeutics: It’s a biotech company that borrows its name from the groundbreaking gene editing technology CRISPR. As of last year, the company has earned FDA approval for a CRISPR-based treatment for two relatively rare diseases, sickle cell disease and beta thalassemia.
But CRISPR Therapeutics CEO Sam Kulkarni is now turning the company’s attention to more common conditions; his team is testing ways to use the technology to edit genes responsible for certain cases of high cholesterol and autoimmune diseases like lupus.
Because these affect a larger population of people, Kulkarni is also committed to making the CRISPR more accessible in cost and convenience. “This marks a shift…that will bring [CRISPR] medicines in a more scalable and affordable manner to patients.” Kulkarni says. “And it’s going to happen in this decade.”
Vertex Pharmaceuticals: Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S. FDA, called Casgevy, which treats sickle-cell disease and beta thalassemia; received approval for its fifth cystic fibrosis treatment, and in January, also earned FDA approval for the first non-opioid pain killer, Journavx, in more than two decades.
CEO Dr. Reshma Kewalramani combines medical, research, and business experience to lead the 36-year-old company. She has continued the drug development pathway on which the company was founded: rational drug design, meaning designing drugs to address a known biological process, rather than spending time with the traditional trial and error practice of combining and testing chemicals in the hope of landing on one that has the desired effect.
READ: Sneha Mantri named first CMO of Parkinson’s Foundation (July 18, 2025)
Following the launch of Casgevy, which allows people with sickle cell disease to receive a single CRISPR gene therapy to address the genetic mutation responsible for their disease, Vertex is continuing to pursue what Kewalramani calls “one and done curative medicines.”
They are in the late stages of testing a cell-based treatment for type 1 diabetes that could potentially help people skip regular insulin injections by giving them healthy insulin-making pancreatic beta cells.
The company is also developing new treatments for chronic kidney disease, for which there have not been new options in almost a decade, and in 2024, Vertex bought Alpine Immune Sciences for $4.9 billion to accelerate its search for novel kidney treatments. “We are simply not interested in making me-too medicines,” says Kewalramani.